Oligodendrogliomas Lacking O⁶-Methylguanine-DNA-Methyltransferase Expression

References

• Bhakat KK, Mitra S. CpG methylation-dependent repression of the human 06-methylguanine-DNA methyltrans-ferase gene linked to chromatin structure alteration. Carcinogenesis 2003; 24 (8): 1337–45.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Matsumoto K, Nakabeppu Y, Iwaki T. A com-parative immunohistochemistry of 06-methylguanine-DNA methyltransferase and p53 in diffusely infiltrating astrocy-tomas. Neuropathology 2003; 23 (3): 203–9.
   PubMed Web of Science ®Google Scholar
• Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002; 8 (8): 2725–34.
   PubMed Web of Science ®Google Scholar
• Gerson SL. MGMT: its role in cancer aetiology and can-cer therapeutics. Nat Rev Cancer 2004; 4 (4): 296–7.
   PubMed Web of Science ®Google Scholar
• EsteIler M, Hamilton Sr, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene 06-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59 (4): 793–7.
   PubMed Web of Science ®Google Scholar
• Blanc JL, Wager M, Guilhot J, et al. Correlation of clin-ical features and methylation status of MGMT gene promoter in glioblastomas. J Neuro-Oncol 2004; (3) 68: 275-83.
   Google Scholar
• Kamiro T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y. Correlation between promoter hypermetilation of the 06-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 2004; 54 (2): 349–57.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S et al. Clinical trial sustantiates the predictive value of 06-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 15 (6): 1871-4.
   Google Scholar
• Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T. promoter hypermethylation of the repair gene 06-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003; 13 (2): 176–84.
   PubMed Web of Science ®Google Scholar
• Balaña C, Ramirez JL, Taron M et al. 06-methylgua-nine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-Bis(2-chloroethyl)-1-nitrosourea but not temozolamide plus cisplatin in glioblastoma multi-forme. Clin Cancer Res 2003; 9 (4): 1461-68.
   PubMed Web of Science ®Google Scholar
• Tano K, Dunn WC, Darroudi F et al. Amplification of the DNA repair gene 06-methylguanine-DNA methyltrans-ferase associated with resistance to alkylating drugs in a mam-malian cell line. J Biol Chem 1997; 272 (20): 13250-54.
   Google Scholar
• Andersson U, Malmer B, Bergenheim AT, Brannstrom, Henriksson R. Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 2004; 23 (1): 21–27.
   PubMed Web of Science ®Google Scholar
• Gerson SL. Clinical relevance of MGMT in the treat-ment of cancer. J Clin Oncol 2002; 20 (4): 2388–99.
   PubMed Web of Science ®Google Scholar
• Nagame M, Asai A, Shibui S, Nomura K, Kuchino Y. Application of antisense ribonucleic acid complementary to 06-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas. Neurosurgery 1997; 41 (2): 434–41.
   PubMed Web of Science ®Google Scholar
• Quinn JA, Pluda J, Dolan ME et al. Phase II trial of carmustine plus 06-Benzylguanine for patients with nutro-sourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002; 20 (9): 2277–83.
   PubMed Web of Science ®Google Scholar
• Silber JR, Bobola MS, Ghathan S, Blank A, Kolstoe DD, Berger MS. 06-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor charac-teristics. Cancer Res 1998; 58 (4): 1068–73.
   PubMed Web of Science ®Google Scholar
• Kleihues P, Cavenee WK: Pathology and Genetics. Tumor of the Nervous System. World Health Organization Classification of Tumours. Lyon, IARC, 2000.
   Google Scholar
• Cairncross JG, Ueki K, Zlatescu C et al. Specific genet-ic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90 (19): 1473–9.
   Google Scholar
• Ino Y, Zlatescu MC, Sasaki H et al. Long survival and therapeutic responses in patients with histologically disparate high grade gliomas demonstrating chromosome lp loss. J Neurosurg 2000; 92 (6): 983–90.
   Google Scholar
• Ino Y, Betensky RA, Zlatescu MC et al. Molecular sub-types of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7 (4): 839–45.
   PubMed Web of Science ®Google Scholar
• Smith JS, Perry A, Sorrel TJ et al. Alterations of chromosome arms lp and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18 (3): 636–45.
   Google Scholar
• Ohe N, Saio M, Kijima M et al. In situ detection of 06-methylguanine-DNA methyltransferase messenger RNA in paraffin-embedded human astrocytic tumor tissues by nested in situ RT-PCR is useful in predicting chemotherapy-resistance of tumors. Int J Oncol 2003; 22 (3): 543-9.
   Google Scholar
• Nutt CL, Costello JF, Bambrick LL et al. 06-methyl-guanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage. Can J Neurol Sci 1995; 22 (2): 111–5.
   PubMed Web of Science ®Google Scholar
• Nutt CL, Noble M, Chambers AF, Cairncross JG. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlates with differential response of oligodendrogliomas and astrocytomas to chemotherapy. Cancer Res 2000; 60 (17): 4812–18.
   PubMed Web of Science ®Google Scholar
• Dolan ME, Moschel RC, Pegg AE. Depletion of mam-malian 06-alkylguanine-DNA alkyltransferase activity by 06-Benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Prod Natl Acad Sci USA 1990; 87 (14): 5368–72.
   PubMed Web of Science ®Google Scholar
• Daniels DS, Mol CD, Arvai AS, Kanugula S, Pegg AE, Tainer JA. Active and alkylated human AGT structures: a novel zinc site, inhibitor and extra helical base binding. EMBI J 2000; 3 (7): 1719–30.
   Web of Science ®Google Scholar
• Spiro TP, Gerson SL, Liu L et al. 06-Benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 1999; 59 (10): 2402-10.
   PubMed Web of Science ®Google Scholar
• Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermetilation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005; 113: 379–385.
   PubMed Web of Science ®Google Scholar
• Alonso ME, Bello MJ, Gonzalez-Gomez P et al. Aberrant promoter methylation of multiple genes in oligoden-drogliomas and ependymomas. Cancer Genet Cytogenet 2003; 144 (2): 134–42.
   PubMedGoogle Scholar
• Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC, Pegg AE. Thresholds of 06-Alchylguanine-DNA Alkyltransferase which confer significant resistance of human glial Tumor xenografts to treatment with 1,3-Bis(2-chloroethyl)-1-nitrosourea or Temozolomide. Clin Cancer Res 2001; 7: 421–28
   PubMed Web of Science ®Google Scholar